albendazole and atovaquone

albendazole has been researched along with atovaquone in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	2 (25.00)	29.6817
2010's	2 (25.00)	24.3611
2020's	3 (37.50)	2.80

Authors

Authors	Studies
Brun, R; Dong, Y; Hemphill, A; Kaiser, M; Matile, H; Nehrbass-Stuedli, A; Vennerstrom, JL; Wang, X; Wittlin, S	1
Bathurst, I; Burrows, JN; Charman, SA; Cross, RM; Flanigan, DL; Fronczek, FR; Guida, WC; Kyle, DE; LaCrue, AN; Maignan, JR; Manetsch, R; Monastyrskyi, A; Mutka, TS; Sáenz, FE; Shackleford, DM; White, KL; Wojtas, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Ahn, KJ; Anderson, MO; Baum, J; Belanger, B; Chaplan, CA; Cheung, A; Churchyard, A; Crespo, B; DiBernardo, C; Eagon, S; Eribez, K; Falade, MO; Gamo, FJ; García-Barbazán, I; Guy, RK; Hammill, JT; Kashtanova, AS; Kim, K; Kimball, JJ; Koch, G; Laleu, B; Lazaro, H; Loop, L; Mittal, N; Rice, AL; Sigal, M; Takahashi, R; Tryhorn, JE; Wilkinson, SP; Winzeler, EA; Yniguez, K	1
Asakawa, AH; Brockmeyer, F; Casandra, D; Huang, L; Kyle, DE; LaCrue, AN; Maher, SP; Maignan, JR; Manetsch, R; Mashkouri, S; Monastyrskyi, A; Padin-Irizarry, V; Parvatkar, PT; Sakhno, YI; Zhao, Y	1
Angelici, E; Canipari, R; Colombo, D; Contini, C; Cultrera, R; Prini, E; Sechi, T	1
Dressman, JB; Reppas, C	1
Enkai, S; Inaoka, DK; Irie, T; Kita, K; Kouguchi, H; Yagi, K	1

Reviews

2 review(s) available for albendazole and atovaquone

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2000, Volume: 11 Suppl 2 Topics: Administration, Oral; Albendazole; Animals; Antiprotozoal Agents; Atovaquone; Biopharmaceutics; Buffers; Chemistry, Pharmaceutical; Gastric Emptying; Gastric Mucosa; Humans; Intestine, Small; Models, Biological; Naphthoquinones; Particle Size; Solubility	2000

Article

Year

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.

Drug discovery today, 2016, Volume: 21, Issue:4

Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2000, Volume: 11 Suppl 2

Topics: Administration, Oral; Albendazole; Animals; Antiprotozoal Agents; Atovaquone; Biopharmaceutics; Buffers; Chemistry, Pharmaceutical; Gastric Emptying; Gastric Mucosa; Humans; Intestine, Small; Models, Biological; Naphthoquinones; Particle Size; Solubility

2000

Other Studies

6 other study(ies) available for albendazole and atovaquone

Article	Year
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160). Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8 Topics: Animals; Antimalarials; Artemisinins; Eukaryota; Heterocyclic Compounds, 1-Ring; Iron; Parasitic Sensitivity Tests; Peroxides; Plasmodium falciparum; Sesquiterpenes; Spiro Compounds	2007
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium. Journal of medicinal chemistry, 2014, Nov-13, Volume: 57, Issue:21 Topics: Animals; Antimalarials; Humans; Inhibitory Concentration 50; Malaria; Mice; Microsomes, Liver; Parasitemia; Plasmodium; Plasmodium berghei; Quinolones; Structure-Activity Relationship	2014
Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4- Journal of medicinal chemistry, 2020, 10-22, Volume: 63, Issue:20 Topics: Antimalarials; Cell Line; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Models, Molecular; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrazoles; Pyridines; Structure-Activity Relationship	2020
Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1 Journal of medicinal chemistry, 2021, 05-27, Volume: 64, Issue:10 Topics: Administration, Oral; Animals; Antimalarials; Cyclization; Disease Models, Animal; Ethers; Female; Half-Life; Hydrogen-Ion Concentration; Malaria; Mice; Mice, Inbred BALB C; Plasmodium falciparum; Prodrugs; Quinolones; Solubility; Structure-Activity Relationship	2021
Employment of terbinafine against Pneumocystis carinii infection in rat models. The British journal of dermatology, 1996, Volume: 134 Suppl 46 Topics: Administration, Oral; Albendazole; Animals; Antifungal Agents; Atovaquone; Drug Administration Schedule; Immunosuppression Therapy; Lung; Naphthalenes; Naphthoquinones; Pneumonia, Pneumocystis; Rats; Rats, Sprague-Dawley; Terbinafine; Trimethoprim, Sulfamethoxazole Drug Combination	1996
In vivo efficacy of combination therapy with albendazole and atovaquone against primary hydatid cysts in mice. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021, Volume: 40, Issue:9 Topics: Albendazole; Animals; Antiparasitic Agents; Atovaquone; Drug Therapy, Combination; Echinococcosis; Echinococcus multilocularis; Female; Mice; Mice, Inbred BALB C	2021